Crossmark

Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume

Crossref DOI link: https://doi.org/10.1186/s12885-020-06925-y

Published Online: 2020-05-18

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tribukait, Bernhard http://orcid.org/0000-0002-2151-3097
License Information

Text and Data Mining valid from 2020-05-18

Version of Record valid from 2020-05-18
More Information

Article History

Received: 12 August 2019

Accepted: 3 May 2020

First Online: 18 May 2020

Ethics approval and consent to participate

: The study was approved by the Ethics Committee at Karolinska University Hospital, 2007/1529–31/2 which had jurisdiction for all participating centers. All patients received oral and written information and consented to participate.

: Not applicable.

: BT is a shareholder in AroCell Ab. The manuscript is written completely independent of the company.

Document is current

Any future updates will be listed below